Market Closed -
Nasdaq
04:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
1.33
USD
|
+2.31%
|
|
+2.31%
|
-32.49%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
450.3
|
96.44
|
95.07
|
64.18
|
-
|
-
|
Enterprise Value (EV)
1 |
218.1
|
-60.5
|
95.07
|
64.18
|
64.18
|
64.18
|
P/E ratio
|
-10.3
x
|
-1.4
x
|
-1.21
x
|
-0.86
x
|
-0.88
x
|
-0.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
14.5
x
|
6.18
x
|
10.4
x
|
9.17
x
|
5.94
x
|
4.34
x
|
EV / Revenue
|
14.5
x
|
6.18
x
|
10.4
x
|
9.17
x
|
5.94
x
|
4.34
x
|
EV / EBITDA
|
-13,403,315
x
|
-1,374,778
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-7.26
x
|
-1.28
x
|
-
|
-0.78
x
|
-0.7
x
|
-0.66
x
|
FCF Yield
|
-13.8%
|
-78.3%
|
-
|
-128%
|
-143%
|
-151%
|
Price to Book
|
1.42
x
|
0.54
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
35,907
|
36,257
|
48,258
|
48,258
|
-
|
-
|
Reference price
2 |
12.54
|
2.660
|
1.970
|
1.330
|
1.330
|
1.330
|
Announcement Date
|
3/17/22
|
3/14/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
30.98
|
15.62
|
9.16
|
7
|
10.8
|
14.8
|
EBITDA
|
-44.56
|
-33.59
|
-70.15
|
-
|
-
|
-
|
-
|
EBIT
1 |
-44.52
|
-34.14
|
-70.9
|
-75.42
|
-79.78
|
-88.15
|
-93.42
|
Operating Margin
|
-
|
-110.18%
|
-453.99%
|
-823.33%
|
-1,139.64%
|
-816.16%
|
-631.21%
|
Earnings before Tax (EBT)
1 |
-
|
-34.12
|
-68.76
|
-68.33
|
-76.59
|
-85.39
|
-90.55
|
Net income
1 |
-44.26
|
-34.12
|
-68.76
|
-68.17
|
-74.73
|
-80.62
|
-85.59
|
Net margin
|
-
|
-110.1%
|
-440.29%
|
-744.17%
|
-1,067.52%
|
-746.47%
|
-578.28%
|
EPS
2 |
-16.02
|
-1.220
|
-1.900
|
-1.630
|
-1.548
|
-1.510
|
-1.474
|
Free Cash Flow
1 |
-
|
-62.01
|
-75.54
|
-
|
-82.44
|
-91.64
|
-97.04
|
FCF margin
|
-
|
-200.14%
|
-483.67%
|
-
|
-1,177.67%
|
-848.56%
|
-655.64%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/21
|
3/17/22
|
3/14/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
3.746
|
20.22
|
3.384
|
0.382
|
6.402
|
5.45
|
5.313
|
2.004
|
1.185
|
0.659
|
2.333
|
2.333
|
2.333
|
2.333
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.52
|
2.792
|
-16.96
|
-20.95
|
-17.88
|
-15.11
|
-15.52
|
-18.49
|
-19.5
|
-21.91
|
-19.74
|
-19.31
|
-20.27
|
-20.45
|
-
|
Operating Margin
|
-387.67%
|
13.81%
|
-501.24%
|
-5,484.55%
|
-279.23%
|
-277.32%
|
-292.02%
|
-922.65%
|
-1,645.82%
|
-3,324.43%
|
-846.19%
|
-827.43%
|
-868.9%
|
-876.52%
|
-
|
Earnings before Tax (EBT)
1 |
-14.52
|
2.797
|
-16.84
|
-20.49
|
-17.34
|
-14.1
|
-14.22
|
-17.12
|
-17.34
|
-19.65
|
-18.88
|
-18.46
|
-19.49
|
-19.76
|
-
|
Net income
1 |
-14.52
|
2.797
|
-16.84
|
-20.49
|
-17.34
|
-14.1
|
-14.22
|
-17.12
|
-17.34
|
-19.49
|
-18.88
|
-18.46
|
-19.49
|
-19.76
|
-15.55
|
Net margin
|
-387.48%
|
13.83%
|
-497.61%
|
-5,364.14%
|
-270.82%
|
-258.66%
|
-267.63%
|
-854.04%
|
-1,463.54%
|
-2,957.36%
|
-809.14%
|
-790.99%
|
-835.14%
|
-847%
|
-
|
EPS
2 |
-0.4000
|
0.2400
|
-0.4700
|
-0.5700
|
-0.4800
|
-0.3900
|
-0.3900
|
-0.4400
|
-0.4000
|
-0.4000
|
-0.4125
|
-0.3900
|
-0.3925
|
-0.3900
|
-0.3200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/17/22
|
5/12/22
|
8/11/22
|
11/7/22
|
3/14/23
|
5/15/23
|
8/10/23
|
11/9/23
|
3/12/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
232
|
157
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-62
|
-75.5
|
-
|
-82.4
|
-91.6
|
-97
|
ROE (net income / shareholders' equity)
|
-
|
-63.9%
|
-38.8%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
8.830
|
4.890
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-2.150
|
-2.050
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.76
|
1.43
|
-
|
1.94
|
1.8
|
1.49
|
Capex / Sales
|
-
|
5.68%
|
9.16%
|
-
|
27.71%
|
16.67%
|
10.03%
|
Announcement Date
|
3/5/21
|
3/17/22
|
3/14/23
|
3/12/24
|
-
|
-
|
-
|
Last Close Price
1.33
USD Average target price
8.333
USD Spread / Average Target +526.57% Consensus |
1st Jan change
|
Capi.
|
---|
| -32.49% | 64.18M | | +1.77% | 42.86B | | +47.70% | 41.36B | | +12.24% | 42.74B | | -8.83% | 27.68B | | +7.44% | 25.15B | | -23.01% | 18.63B | | +30.56% | 12.37B | | -1.82% | 11.92B | | +8.35% | 11.21B |
Other Biotechnology & Medical Research
|